Xenetic Biosciences, Inc. (XBIO)
NASDAQ: XBIO · Real-Time Price · USD
2.460
-0.150 (-5.75%)
Apr 1, 2025, 4:00 PM EDT - Market closed
Xenetic Biosciences Revenue
In the year 2024, Xenetic Biosciences had annual revenue of $2.50M, down -1.56%. Xenetic Biosciences had revenue of $648.82K in the quarter ending December 31, 2024, a decrease of -3.44%.
Revenue (ttm)
$2.50M
Revenue Growth
-1.56%
P/S Ratio
1.61
Revenue / Employee
$1,250,142
Employees
2
Market Cap
3.79M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.50M | -39.70K | -1.56% |
| Dec 31, 2023 | 2.54M | 833.06K | 48.80% |
| Dec 31, 2022 | 1.71M | 546.23K | 47.06% |
| Dec 31, 2021 | 1.16M | 723.75K | 165.64% |
| Dec 31, 2020 | 436.94K | 419.88K | 2,460.31% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
XBIO News
- 6 days ago - Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma - Accesswire
- 13 days ago - Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results - Accesswire
- 19 days ago - Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses - Accesswire
- 4 weeks ago - Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting - Accesswire
- 3 months ago - Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment - Accesswire
- 3 months ago - Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform - Accesswire
- 4 months ago - Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program - Accesswire
- 4 months ago - Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis - Accesswire